Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Investigation of Novel Variants in Familial Multiple Sclerosis Through Family-based Association Tests and Segregation Analyses
Multiple Sclerosis
S17 - Multiple Sclerosis: Immunology/Basic Sciences (2:12 PM-2:24 PM)
007

Multiply affected families, characterized by a high degree of consanguinity, have offered unique advantages in search of novel variants. 

Our study aimed to discover novel, rare variants associated with the risk of familial multiple sclerosis (MS) in a cohort of 45 multi-affected families.

Three distinct association tools, namely the familial Functional Haplotype Association Test (famFHAT), Exomiser, and the Protein Variation Analysis and Annotation System Tool (pVAAST), were employed to analyze exome sequencing data from 101 patients with MS and 53 unaffected relatives.

Among these tools, famFHAT emerged as the most robust and reliable tool, revealing significant findings at a stringent p-value threshold of <0.001. Notably, two genes, UMODL1 and ATXN3, drew our attention due to their roles in MS phenotypes, which were supported by functional evidence, mouse models, and expression patterns in the literature. UMODL1 is involved in extracellular matrix and neutrophil migration, and ATXN3 is associated with the innate immune system pathway. To further investigate the highlighted genes, we conducted segregation analysis in 45 families using the full-likelihood Bayes factor (FLB) algorithm, following ACMG guidelines and utilizing penetrance values of 0.001, 0.6, and 0.6. Specifically, there were seven variants with a minor allele frequency cutoff of 0.02 in UMODL1, all with protein-altering consequences and absent in non-MS family members. These UMODL1 exonic variations showed segregation across nine families. Notably, the rs114358105 stop gain and the rs150611312 missense variants were observed in diverse familial patterns and among siblings, respectively.

Our study successfully identified novel, rare variants associated with familial MS, with famFHAT as the most reliable tool in our study. These findings highlighted the significance of genes, such as UMODL1 and ATXN3, in MS pathogenesis, providing insights into potential pathogenic implications in familial MS cohorts.

Authors/Disclosures
Elif Everest, PhD (National Institutes of Health)
PRESENTER
Ms. Everest has received personal compensation in the range of $50,000-$99,999 for serving as a postdoctoral visiting fellow with National Institutes of Health.
Aksel Siva, MD (Istanbul University Cerrahpasa School of Medicine) Dr. Siva has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi-Genzyme. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen - TR. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abdi Ibrahim Ilac - TR. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck Serono . The institution of Dr. Siva has received research support from Turkish MS Society. The institution of Dr. Siva has received research support from The Scientific and Technological Research Council Of Turkey - Health Sciences Research Grants.
Alper Bulbul No disclosure on file
Melih Tutuncu, MD (ISTANBUL UNIVERSITESI CERRAHPASA TIP FAKULTESI) Melih Tutuncu has nothing to disclose.
Ugur Uygunoglu (Cerrahpasa) Ugur Uygunoglu has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche Turkey . The institution of Ugur Uygunoglu has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. The institution of Ugur Uygunoglu has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen Idec/Gen Pharma of Turkey.
Sabahattin Saip No disclosure on file
Caner Feyzi Demir Caner Feyzi Demirkaya has nothing to disclose.
Cavit Boz, MD Dr. Boz has nothing to disclose.
Mehmet Fatih Yetkin (Erciyes university) No disclosure on file
Husnu Efendi, MD (Gen Pharmacenticals) The institution of Dr. Efendi has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Alexion. The institution of Dr. Efendi has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Sanofi. The institution of Dr. Efendi has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Roche. The institution of Dr. Efendi has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Novartis.
Sena Destan Bunul No disclosure on file
Taskin Duman (Flukara Numune Hospital) Dr. Duman has nothing to disclose.
Mehmet Tecellioglu No disclosure on file
Murat Terzi, PhD (19 Mayis Universitesi) Dr. Terzi has nothing to disclose.
Sedat Sen No disclosure on file
Rana Karabudak, MD (Academic Neurologist) Dr. Karabudak has nothing to disclose.
Asli Tuncer No disclosure on file
Cihat Uzunkopru (Katip Celebi Univ. Atatürk EAH) Cihat Uzunkopru has nothing to disclose.
Omer F. Turan, MD Dr. Turan has nothing to disclose.
Serkan Demir, MD (DR.ILHAN VARANK HASTANESI) Dr. Demir has nothing to disclose.
Tuncay Gunduz, MD (ISTANBUL UNIVERSITESI NOROLOJI SERVISI) Dr. Gunduz has nothing to disclose.
Ufuk Aluclu, PhD No disclosure on file
Haluk Gumus No disclosure on file
Umut Voyvoda (Acibadem University) No disclosure on file
Osman Sezerman No disclosure on file
Eda Turanli No disclosure on file